One Gene Editing Shot Cut Bad Cholesterol by Half for a Year

Keypoints

• A Cleveland Clinic trial tested a one-time CRISPR treatment called CTX310
• At the highest dose, LDL (bad) cholesterol dropped 52.5% after 12 months
• Triglycerides fell by 47.8% at the same dose
• Only 15 people took part, all with hard to treat blood fat problems
• No serious side effects linked to the treatment were reported in the first year
• Results were published in the New England Journal of Medicine

Most people manage cholesterol with daily pills. This early trial points to a very different idea, one treatment that works for a long time. The therapy is given as a single infusion. It carries CRISPR gene editing tools to the liver and switches off a gene called ANGPTL3. That gene helps control the fats floating in your blood, so turning it off lowers both LDL cholesterol and triglycerides.

The patients all had lipid disorders that medicines had not controlled well enough. After one year, those on the highest dose still had about half the cholesterol and triglycerides they started with. Doctors say the lasting effect was the most impressive part.

Safety looked good so far. No serious problems tied to the treatment showed up during the year. Now for the caveat. This is an early Phase 1 trial with just 15 people, and the therapy is still experimental. The study was also funded by CRISPR Therapeutics. Researchers plan to follow the patients for another 15 years, which is standard for gene editing therapies, and want to test it in more people.